Pacira BioSciences
PCRX
257 hedge funds and large institutions have $2.9B invested in Pacira BioSciences in 2020 Q3 according to their latest regulatory filings, with 42 funds opening new positions, 92 increasing their positions, 84 reducing their positions, and 31 closing their positions.
35% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 31
13% more capital invested
Capital invested by funds: $2.56B → $2.9B (+$340M)
4% more funds holding
Funds holding: 248 → 257 (+9)
10% more repeat investments, than reductions
Existing positions increased: 92 | Existing positions reduced: 84
2.73% less ownership
Funds ownership: 115.66% → 112.93% (-2.7%)
29% less funds holding in top 10
Funds holding in top 10: 7 → 5 (-2)
59% less call options, than puts
Call options by funds: $2.95M | Put options by funds: $7.13M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NPIC
Neumeier Poma Investment Counsel
Carmel,
California
|
+$25.1M |
| 2 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$24.4M |
| 3 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$17.4M |
| 4 |
Wells Fargo
San Francisco,
California
|
+$17.3M |
| 5 |
SCM
Spyglass Capital Management
San Francisco,
California
|
+$16.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$27M |
| 2 |
Westfield Capital Management
Boston,
Massachusetts
|
-$26.1M |
| 3 |
HM
HealthCor Management
New York
|
-$21.3M |
| 4 |
BlackRock
New York
|
-$21M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$10.5M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
NAM
276
Nexpoint Asset Management
Dallas,
Texas
| – | -$291K | -5,550 | Closed |
|
|
PM
277
Parametrica Management
Wanchai,
Hong Kong
| – | -$275K | -5,249 | Closed |
|
|
CANY
278
Caxton Associates (New York)
New York
| – | -$255K | -4,866 | Closed |
|
279
Cambridge Investment Research Advisors
Fairfield,
Iowa
| – | -$232K | -4,420 | Closed |
|
|
II
280
Inspire Investing
Meridian,
Idaho
| – | -$218K | -4,154 | Closed |
|
281
Lazard Asset Management
New York
| – | -$191K | -3,645 | Closed |
|
|
PHK
282
Point72 Hong Kong
Hong Kong
| – | -$142K | -2,706 | Closed |
|
|
PAG
283
Private Advisor Group
Morristown,
New Jersey
| – | -$94K | -1,786 | Closed |
|
|
LIA
284
LS Investment Advisors
Bloomfield Hills,
Michigan
| – | -$75K | -1,437 | Closed |
|
|
WR
285
Watson Rebecca
| – | -$52K | -1,000 | Closed |
|
|
MWA
286
MFA Wealth Advisors
Pittsburgh,
Pennsylvania
| – | -$12.5K | -238 | Closed |
|
|
FHC
287
First Horizon Corporation
Memphis,
Tennessee
| – | +$174 | +3 | New |
|
PCRX Hedge Fund Activity: Q3 2020 in Review
257 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Pacira BioSciences (PCRX) for Q3 2020, worth a combined $2.9B — up 13% from $2.56B a quarter earlier.
Buyers outnumbered sellers: 42 funds opened new PCRX positions and 31 closed out — a net gain of 11 holders — while 92 added to existing stakes and 84 trimmed.
The largest buyer was Neumeier Poma Investment Counsel, opening a new position worth an estimated $25.1M. The largest seller was Deerfield Management, cutting an estimated $27M.
- 257 institutional investors held Pacira BioSciences (PCRX) as of Q3 2020, up from 248 in Q2 2020.
- Funds reported $2.9B of Pacira BioSciences stock for Q3 2020, up 13% quarter-over-quarter.
- 42 funds opened new Pacira BioSciences positions in Q3 2020 and 31 closed out, a net change of +11 holders.
- The largest Pacira BioSciences buyer in Q3 2020 was Neumeier Poma Investment Counsel, an estimated $25.1M added.
- The largest Pacira BioSciences seller in Q3 2020 was Deerfield Management, an estimated $27M sold.
Based on aggregated 13F filings for Q3 2020.